Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.51 |
| ▸ | CA1 | P00915 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.42 |
| ▸ | GRN | P28799 | 1/20 | 0.42 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.42 |
| ▸ | UBASH3B | Q8TF42 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KLK7 | P49862 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1827820 | 0.85 | TAS1R3 (0.50) | KMT2ASMYD3MEN1KDM4ELMNA | |
| SCHEMBL1828604 | 0.84 | PTPN1 (0.56) | CA2CA1PIN1UBASH3BL3MBTL1 | |
| SCHEMBL13322387 | 0.82 | SMYD3 (0.51) | KMT2ASMYD3MEN1KDM4ELMNA | |
| SCHEMBL12659172 | 0.77 | SMYD3 (0.49) | KMT2ASMYD3MEN1KDM4ELMNA | |
| SCHEMBL12658563 | 0.75 | ALDH1A1 (0.59) | KDM4ELMNARAB9AALDH1A1 | |
| SCHEMBL6767250 | 0.75 | RAB9A (0.64) | KMT2ASMYD3MEN1KDM4ELMNA | |
| SCHEMBL12984637 | 0.72 | PIN1 (0.70) | CA2CA1PIN1 | |
| SCHEMBL12984634 | 0.72 | PIN1 (0.70) | CA2CA1PIN1 | |
| SCHEMBL6768125 | 0.72 | SMYD3 (0.55) | KMT2ASMYD3MEN1KDM4ELMNA | |
| SCHEMBL2792747 | 0.72 | CA2 (0.66) | CA2CA1CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100323999-A1 | Therapeutic Molecules and Methods-1 | MORAND ERIC FRANCIS | 2010-12-23 | — | — | US | claimed |
| US-7709514-B2 | Therapeutic molecules and methods-1 | CORTICAL PTY LTD (AU) | 2010-05-04 | — | — | US | claimed |
| US-20060154977-A1 | Therapeutic molecules and methods-1 | CORTICAL PTY LTD, CORPORATION | 2006-07-13 | — | — | US | claimed |
| EP-1511736-A4 | THERAPEUTIC MOLECULES AND METHODS-1 | CORTICAL PTY LTD (AU) | 2006-06-07 | — | — | EP | claimed |
| EP-1511736-A1 | THERAPEUTIC MOLECULES AND METHODS-1 | Cortical Pty Ltd (AU) | 2005-03-09 | — | — | EP | claimed |
| WO-2003104203-A1 | THERAPEUTIC MOLECULES AND METHODS-1 | CORTICAL PTY LTD (AU) | 2003-12-18 | — | — | WO | claimed |
| EP-2319838-A1 | Therapeutic Molecules and Methods-1 | Cortical Pty Ltd (AU) | 2011-05-11 | — | — | EP | disclosed |
| EP-2319838-A1 | Therapeutic Molecules and Methods-1 | Cortical Pty Ltd (AU) | 2011-05-11 | — | — | EP | disclosed |
| US-20100323999-A1 | Therapeutic Molecules and Methods-1 | MORAND ERIC FRANCIS | 2010-12-23 | — | — | US | disclosed |
| US-20100323999-A1 | Therapeutic Molecules and Methods-1 | MORAND ERIC FRANCIS | 2010-12-23 | — | — | US | disclosed |
| US-20100323999-A1 | Therapeutic Molecules and Methods-1 | MORAND ERIC FRANCIS | 2010-12-23 | — | — | US | disclosed |
| US-7709514-B2 | Therapeutic molecules and methods-1 | CORTICAL PTY LTD (AU) | 2010-05-04 | — | — | US | disclosed |
| US-7709514-B2 | Therapeutic molecules and methods-1 | CORTICAL PTY LTD (AU) | 2010-05-04 | — | — | US | disclosed |
| US-7709514-B2 | Therapeutic molecules and methods-1 | CORTICAL PTY LTD (AU) | 2010-05-04 | — | — | US | disclosed |
| US-20060154977-A1 | Therapeutic molecules and methods-1 | CORTICAL PTY LTD, CORPORATION | 2006-07-13 | — | — | US | disclosed |
| EP-1511736-A4 | THERAPEUTIC MOLECULES AND METHODS-1 | CORTICAL PTY LTD (AU) | 2006-06-07 | — | — | EP | disclosed |
| EP-1511736-A1 | THERAPEUTIC MOLECULES AND METHODS-1 | Cortical Pty Ltd (AU) | 2005-03-09 | — | — | EP | disclosed |
| WO-2003104203-A1 | THERAPEUTIC MOLECULES AND METHODS-1 | CORTICAL PTY LTD (AU) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154977-A1 | Therapeutic molecules and methods-1 | MIF, IL1B, IL1A | CA2 2519/4885CA1 960/4885KMT2A 4517/4885 |
| US-20100323999-A1 | Therapeutic Molecules and Methods-1 | MIF, IL1B, IL1A | CA2 2519/4885CA1 960/4885KMT2A 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.